In this edition
– Use of clinical and echocardiographic evaluation to assess HF risk
– Optimisation of evidence-based HF medications after acute admission
– Implantable haemodynamic monitors improve survival in HFREF
– Neuropeptide Y: elevated in HF and predicts outcomes
– Bariatric surgery and weight-loss pharmacotherapies in HF with obesity
– Prognostic value of HGI in HFREF
– GFR decline after dapagliflozin in HFMREF/HFPEF
– First-phase EF predicts adverse outcomes in HF
– CV medication utilisation trends among US veterans with HF or CAD + diabetes